Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Jun;33(6):623–627. doi: 10.1111/j.1365-2125.1992.tb04091.x

Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.

D N John 1, S Fort 1, M J Lewis 1, D K Luscombe 1
PMCID: PMC1381354  PMID: 1389935

Abstract

1. The pharmacokinetics and pharmacodynamics of verapamil administered via the oral and sublingual routes were compared in a randomised, two-way cross-over study involving six healthy male volunteers. 2. Administered sublingually, a verapamil 40 mg (Securon) crushed tablet produced a significantly higher peak plasma concentration (P less than 0.05), a greater rate of absorption (P less than 0.05), and greater bioavailability (P less than 0.05) when compared with orally administered verapamil 40 mg (Securon). 3. In comparison with oral dosing, PR intervals were significantly (P less than 0.05) prolonged between 30 and 90 min after sublingual verapamil dosing. 4. Correlations between log plasma verapamil concentration and percentage increase in PR interval were greater after sublingual compared with oral dosing in all volunteers.

Full text

PDF
624

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asthana O. P., Woodcock B. G., Wenchel M., Frömming K. H., Schwabe L., Rietbrock N. Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration. Arzneimittelforschung. 1984;34(4):498–502. [PubMed] [Google Scholar]
  2. Dominic J. A., Bourne D. W., Tan T. G., Kirsten E. B., McAllister R. G., Jr The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration. J Cardiovasc Pharmacol. 1981 Jan-Feb;3(1):25–38. doi: 10.1097/00005344-198101000-00003. [DOI] [PubMed] [Google Scholar]
  3. Dominic J., McAllister R. G., Jr, Kuo C. S., Reddy C. P., Surawicz B. Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter. Clin Pharmacol Ther. 1979 Dec;26(6):710–714. doi: 10.1002/cpt1979266710. [DOI] [PubMed] [Google Scholar]
  4. Echizen H., Brecht T., Niedergesäss S., Vogelgesang B., Eichelbaum M. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J. 1985 Feb;109(2):210–217. doi: 10.1016/0002-8703(85)90585-x. [DOI] [PubMed] [Google Scholar]
  5. Echizen H., Vogelgesang B., Eichelbaum M. Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther. 1985 Jul;38(1):71–76. doi: 10.1038/clpt.1985.137. [DOI] [PubMed] [Google Scholar]
  6. Eichelbaum M., Ende M., Remberg G., Schomerus M., Dengler H. J. The metabolism of DL-[14C]verapamil in man. Drug Metab Dispos. 1979 May-Jun;7(3):145–148. [PubMed] [Google Scholar]
  7. Eichelbaum M., Mikus G., Vogelgesang B. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol. 1984 Apr;17(4):453–458. doi: 10.1111/j.1365-2125.1984.tb02371.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Eichelbaum M., Somogyi A. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil. Eur J Clin Pharmacol. 1984;26(1):47–53. doi: 10.1007/BF00546708. [DOI] [PubMed] [Google Scholar]
  9. Hoon T. J., Bauman J. L., Rodvold K. A., Gallestegui J., Hariman R. J. The pharmacodynamic and pharmacokinetic differences of the D- and L-isomers of verapamil: implications in the treatment of paroxysmal supraventricular tachycardia. Am Heart J. 1986 Aug;112(2):396–403. doi: 10.1016/0002-8703(86)90281-4. [DOI] [PubMed] [Google Scholar]
  10. Kacprowicz A. T., Fullinfaw R. O., Bury R. W. High-performance liquid chromatographic measurement of verapamil in plasma using a diol column. J Chromatogr. 1985 Feb 8;337(2):412–415. doi: 10.1016/0378-4347(85)80056-6. [DOI] [PubMed] [Google Scholar]
  11. Kapur P. A., Law T., Watson E. Simultaneous quantitation of verapamil, norverapamil, and N-dealkylated metabolites in human plasma following oral administration. J Chromatogr. 1985 Jan 11;337(1):160–165. doi: 10.1016/0378-4347(85)80024-4. [DOI] [PubMed] [Google Scholar]
  12. McAllister R. G., Jr, Kirsten E. B. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther. 1982 Apr;31(4):418–426. doi: 10.1038/clpt.1982.54. [DOI] [PubMed] [Google Scholar]
  13. Mølgaard H., Bjerregaard P., Jørgensen H. S., Klitgaard N. A. 24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation. Eur J Clin Pharmacol. 1987;33(5):447–453. doi: 10.1007/BF00544233. [DOI] [PubMed] [Google Scholar]
  14. Neugebauer G. Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog. Cardiovasc Res. 1978 Apr;12(4):247–254. doi: 10.1093/cvr/12.4.247. [DOI] [PubMed] [Google Scholar]
  15. Padrini R., Barbieri E., Piovan D., Toffoli M., Motta A., Trevi G. P., Ferrari M. Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man. Eur J Clin Pharmacol. 1985;28(6):653–657. doi: 10.1007/BF00607910. [DOI] [PubMed] [Google Scholar]
  16. Pomfret S. M., Beasley C. R., Challenor V., Holgate S. T. Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. Clin Sci (Lond) 1988 Apr;74(4):351–357. doi: 10.1042/cs0740351. [DOI] [PubMed] [Google Scholar]
  17. Reiter M. J., Shand D. G., Pritchett E. L. Comparison of intravenous and oral verapamil dosing. Clin Pharmacol Ther. 1982 Dec;32(6):711–720. doi: 10.1038/clpt.1982.227. [DOI] [PubMed] [Google Scholar]
  18. Rinkenberger R. L., Prystowsky E. N., Heger J. J., Troup P. J., Jackman W. M., Zipes D. P. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation. 1980 Nov;62(5):996–1010. doi: 10.1161/01.cir.62.5.996. [DOI] [PubMed] [Google Scholar]
  19. Schomerus M., Spiegelhalder B., Stieren B., Eichelbaum M. Physiological disposition of verapamil in man. Cardiovasc Res. 1976 Sep;10(5):605–612. doi: 10.1093/cvr/10.5.605. [DOI] [PubMed] [Google Scholar]
  20. Stern E. H., Pitchon R., King B. D., Guerrero J., Schneider R. R., Wiener I. Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. Chest. 1982 Mar;81(3):308–311. doi: 10.1378/chest.81.3.308. [DOI] [PubMed] [Google Scholar]
  21. Sung R. J., Elser B., McAllister R. G., Jr Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med. 1980 Nov;93(5):682–689. doi: 10.7326/0003-4819-93-5-682. [DOI] [PubMed] [Google Scholar]
  22. Sung R. J., Waxman H. L., Elser B., Juma Z. Treatment of paroxysmal supraventricular tachycardia and atrial flutter-fibrillation with intravenous verapamil: efficacy and mechanism of action. Clin Invest Med. 1980;3(1-2):41–47. [PubMed] [Google Scholar]
  23. Vogelgesang B., Echizen H., Schmidt E., Eichelbaum M. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol. 1984 Nov;18(5):733–740. doi: 10.1111/j.1365-2125.1984.tb02536.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Woodcock B. G., Wörner P., Rietbrock N., Schwabe L., Frömming K. H. Pharmakokinetik und Pharmakodynamik von Verapamil bei gesunden Versuchspersonen nach einmaliger oraler und sublingualer Applikation. Arzneimittelforschung. 1982;32(12):1567–1571. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES